Sector revisions United Therapeutics Corporation

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-08 EDT			5-day change	1st Jan Change
294.42 ^USD	+1.39%		+1.21%	-16.56%

06-30	United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	MT
06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	UNITED THERAPEUTICS CORPORATION							13
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							23
	ABBVIE INC.							27
	NOVO NORDISK A/S							22
	ROCHE HOLDING AG							20
	NOVARTIS AG							19
	ASTRAZENECA PLC							20
	MERCK & CO., INC.							24
	AMGEN INC.							28
	PFIZER, INC.							23
	GILEAD SCIENCES, INC.							26
	VERTEX PHARMACEUTICALS INCORPORATED							28
	SANOFI							23
	BRISTOL-MYERS SQUIBB COMPANY							22
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	GSK PLC							19
	JIANGSU HENGRUI MEDICINE CO., LTD.							18
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							16
	Average							22
	Weighted average by Cap.							23